News Gabather AB

Equities

GABA

SE0010869552

Market Closed - Nasdaq Stockholm Other stock markets 11:22:02 2024-05-17 am EDT			5-day change	1st Jan Change
1.815 ^SEK	-11.89%		-17.87%	+28.72%

Apr. 10	Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	CI
Mar. 18	Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002	Apr. 10	AQ
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	Apr. 10	CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	Mar. 18	MT
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders	Mar. 18	AQ
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	Mar. 18	CI
Gabather reports initial positive results from the EEG/fMRI target engagement study	Mar. 07	AQ
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	Mar. 07	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study	Dec. 22	AQ
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)	Dec. 14	AQ
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	Dec. 14	CI
Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG	Dec. 11	AQ
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	23-10-12	AQ
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	23-10-12	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957	23-04-13	AQ
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	23-04-13	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gabather AB

Equities

GABA

SE0010869552

Summary

Filters